BOCA RATON, Fla., Nov. 3, 2014 /PRNewswire/ -- Breckenridge Pharmaceutical, Inc. announces the approval of Quetiapine Fumarate Tablets. Quetiapine Fumarate Tablets are AB rated to Seroquel a $395 million dollar generic drug marketed by the AstraZeneca group of companies. Seroquel® is an atypical antipsychotic indicated for the treatment of Schizophrenia and Bipolar disorders. The product launch plans are still being finalized.
Breckenridge’s Quetiapine Fumarate Tablets are supplied under a deal with Medikl, Ltd Cyprus and are manufactured and supplied by Alembic Pharmaceutical’s, the ANDA holder. The product will be supplied in 25, 50, 100, 200, 300 AND 400mg strengths.
About Breckenridge:
Breckenridge Pharmaceutical, Inc. is a privately-held pharmaceutical marketing, research and development company founded in 1983 that markets a broad range of generic prescription products in many therapeutic categories. The Breckenridge label is recognized by Wholesalers, Distributors, Chains, and Managed Care Accounts, as well as Retail Pharmacies nationwide. Breckenridge markets in excess of fifty (50) products in a variety of dosage forms and therapeutic categories. www.bpirx.com
SOURCE Breckenridge Pharmaceutical, Inc.
Help employers find you! Check out all the jobs and post your resume.
